Nautilus Biotechnology (NAUT) Enterprise Value (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Enterprise Value of -$84.0 million for Q2 2026, up 12.35% sequentially from -$95.9 million in Q1 2026, and up 43.17% YoY from -$58.7 million in Q2 2025.
Nautilus Biotechnology (NAUT) Enterprise Value (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Enterprise Value for 7 years, with the latest figure at -$84.0 million in Q2 2026.
- Quarterly Enterprise Value rose 43.17% year-over-year to -$84.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$84.0 million (up 43.17% YoY) and the FY2025 annual result came in at -$103.4 million, up 20.39% from the prior year.
- Enterprise Value advanced to -$84.0 million in Q2 2026 per NAUT's latest filing, from -$95.9 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$84.0 million in Q2 2026 and troughed at -$324.1 million in Q1 2022.
- A 5-year average of -$170.8 million and a median of -$165.3 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value sank 47423.79% in 2022, then soared 48.37% in 2023.
- Over 5 years, Enterprise Value stood at -$184.5 million in 2022, then increased by 5.99% to -$173.4 million in 2023, then advanced by 25.1% to -$129.9 million in 2024, then rose by 20.39% to -$103.4 million in 2025, then climbed by 18.74% to -$84.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$84.0 million, -$95.9 million, and -$103.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | -84.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -84.03 Mn |
| Mar 31, 2026 | -95.87 Mn |
| Dec 31, 2025 | -103.41 Mn |
| Sep 30, 2025 | -131.43 Mn |
| Jun 30, 2025 | -147.87 Mn |
| Mar 31, 2025 | -138.81 Mn |
| Dec 31, 2024 | -129.89 Mn |
| Sep 30, 2024 | -140.61 Mn |
| Jun 30, 2024 | -167.44 Mn |
| Mar 31, 2024 | -181.37 Mn |
| Dec 31, 2023 | -173.42 Mn |
| Sep 30, 2023 | -183.29 Mn |
| Jun 30, 2023 | -163.30 Mn |
| Mar 31, 2023 | -167.35 Mn |
| Dec 31, 2022 | -184.47 Mn |
| Sep 30, 2022 | -257.97 Mn |
| Jun 30, 2022 | -299.34 Mn |
| Mar 31, 2022 | -324.12 Mn |
| Dec 31, 2021 | -345.73 Mn |
| Sep 30, 2021 | -347.35 Mn |